Abstract
Congenital hyperinsulinism (CHI) is a rare disease characterized by an unregulated insulin release, leading to hypoglycaemia. It is the most frequent cause of persistent and severe hypoglycaemia in the neonatal period and early childhood. Mutations in 16 different key genes (ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, UCP2, HNF4A, HNF1A, HK1, KCNQ1, CACNA1D, FOXA2, EIF2S3, PGM1 and PMM2) that are involved in regulating the insulin secretion from pancreatic β-cells have been described to be responsible for the underlying molecular mechanisms of CHI. CHI can also be associated with specific syndromes and can be secondary to intrauterine growth restriction (IUGR), maternal diabetes, birth asphyxia, etc. It is important to diagnose and promptly initiate appropriate management as untreated hypoglycaemia can be associated with significant neurodisability. CHI can be histopathologically classified into diffuse, focal and atypical forms. Advances in molecular genetics, imaging techniques (18F-fluoro-l-dihydroxyphenylalanine positron emission tomography/computed tomography scanning), novel medical therapies and surgical advances (laparoscopic pancreatectomy) have changed the management and improved the outcome of patients with CHI. This review article provides an overview of the background, clinical presentation, diagnosis, molecular genetics and therapy for children with different forms of CHI.
-
Research funding: None declared.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
References
1. Aynsley-Green, A, Hussain, K, Hall, J, Saudubray, JM, Nihoul-Fekete, C, De Lonlay-Debeney, P, et al.. Practical management of hyperinsulinism in infancy. Arch Dis Child Fetal Neonatal Ed 2000;82:F98–107. https://doi.org/10.1136/fn.82.2.f98.Suche in Google Scholar PubMed PubMed Central
2. Hussain, K, Blankenstein, O, De Lonlay, P, Christesen, HT. Hyperinsulinaemic hypoglycaemia: biochemical basis and the importance of maintaining normoglycaemia during management. Arch Dis Child 2007;92:568–70. https://doi.org/10.1136/adc.2006.115543.Suche in Google Scholar PubMed PubMed Central
3. Senniappan, S, Shanti, B, James, C, Hussain, K. Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and management. J Inherit Metab Dis 2012;35:589–601. https://doi.org/10.1007/s10545-011-9441-2.Suche in Google Scholar PubMed
4. Yau, D, Laver, TW, Dastamani, A, Senniappan, S, Houghton, JAL, Shaikh, G, et al.. Using referral rates for genetic testing to determine the incidence of a rare disease: the minimal incidence of congenital hyperinsulinism in the UK is 1 in 28,389. PLoS One 2020;15:e0228417. https://doi.org/10.1371/journal.pone.0228417.Suche in Google Scholar PubMed PubMed Central
5. Demirbilek, H, Hussain, K. Congenital hyperinsulinism: diagnosis and treatment update. J Clin Res Pediatr Endocrinol 2017;9:69–87. https://doi.org/10.4274/jcrpe.2017.S007.Suche in Google Scholar PubMed PubMed Central
6. Galcheva, S, Demirbilek, H, Al-Khawaga, S, Hussain, K. The genetic and molecular mechanisms of congenital hyperinsulinism. Front Endocrinol 2019;10:111. https://doi.org/10.3389/fendo.2019.00111.Suche in Google Scholar PubMed PubMed Central
7. Kapoor, RR, Flanagan, SE, Arya, VB, Shield, JP, Ellard, S, Hussain, K. Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism. Eur J Endocrinol 2013;168:557–64. https://doi.org/10.1530/eje-12-0673.Suche in Google Scholar PubMed PubMed Central
8. Avatapalle, HB, Banerjee, I, Shah, S, Pryce, M, Nicholson, J, Rigby, L, et al.. Abnormal neurodevelopmental outcomes are common in children with transient congenital hyperinsulinism. Front Endocrinol 2013;4:60. https://doi.org/10.3389/fendo.2013.00060.Suche in Google Scholar PubMed PubMed Central
9. Hussain, K, Aynsley-Green, A. Management of hyperinsulinism in infancy and childhood. Ann Med 2000;32:544–51. https://doi.org/10.3109/07853890008998834.Suche in Google Scholar PubMed
10. James, C, Kapoor, RR, Ismail, D, Hussain, K. The genetic basis of congenital hyperinsulinism. J Med Genet 2009;46:289–99. https://doi.org/10.1136/jmg.2008.064337.Suche in Google Scholar PubMed
11. Ismail, D, Hussain, K. Role of 18F-DOPA PET/CT imaging in congenital hyperinsulinism. Rev Endocr Metab Disord 2010;11:165–9. https://doi.org/10.1007/s11154-010-9145-1.Suche in Google Scholar PubMed
12. Ashcroft, FM, Harrison, DE, Ashcroft, SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 1984;312:446–8. https://doi.org/10.1038/312446a0.Suche in Google Scholar PubMed
13. Inagaki, N, Gonoi, T, Clement, JP, Namba, N, Inazawa, J, Gonzalez, G, et al.. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 1995;270:1166–70. https://doi.org/10.1126/science.270.5239.1166.Suche in Google Scholar PubMed
14. Gould, GW, Thomas, HM, Jess, TJ, Bell, GI. Expression of human glucose transporters in Xenopus oocytes: kinetic characterization and substrate specificities of the erythrocyte, liver, and brain isoforms. Biochemistry 1991;30:5139–45. https://doi.org/10.1021/bi00235a004.Suche in Google Scholar PubMed
15. Flanagan, SE, Clauin, S, Bellanne-Chantelot, C, de Lonlay, P, Harries, LW, Gloyn, AL, et al.. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 2009;30:170–80. https://doi.org/10.1002/humu.20838.Suche in Google Scholar PubMed
16. Cartier, EA, Conti, LR, Vandenberg, CA, Shyng, SL. Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy. Proc Natl Acad Sci USA 2001;98:2882–7. https://doi.org/10.1073/pnas.051499698.Suche in Google Scholar PubMed PubMed Central
17. Arya, VB, Aziz, Q, Nessa, A, Tinker, A, Hussain, K. Congenital hyperinsulinism: clinical and molecular characterisation of compound heterozygous ABCC8 mutation responsive to Diazoxide therapy. Int J Pediatr Endocrinol 2014;2014:24. https://doi.org/10.1186/1687-9856-2014-24.Suche in Google Scholar PubMed PubMed Central
18. Taylor-Miller, T, Houghton, J, Munyard, P, Kumar, Y, Puvirajasinghe, C, Giri, D. Congenital hyperinsulinism due to compound heterozygous mutations in ABCC8 responsive to diazoxide therapy. J Pediatr Endocrinol Metab 2020;33:671–4. https://doi.org/10.1515/jpem-2019-0457.Suche in Google Scholar PubMed
19. Kumaran, A, Kapoor, RR, Flanagan, SE, Ellard, S, Hussain, K. Congenital hyperinsulinism due to a compound heterozygous ABCC8 mutation with spontaneous resolution at eight weeks. Horm Res Paediatr 2010;73:287–92. https://doi.org/10.1159/000284394.Suche in Google Scholar PubMed
20. Flanagan, SE, Kapoor, RR, Banerjee, I, Hall, C, Smith, VV, Hussain, K, et al.. Dominantly acting ABCC8 mutations in patients with medically unresponsive hyperinsulinaemic hypoglycaemia. Clin Genet 2011;79:582–7. https://doi.org/10.1111/j.1399-0004.2010.01476.x.Suche in Google Scholar PubMed PubMed Central
21. Kapoor, RR, Flanagan, SE, James, CT, McKiernan, J, Thomas, AM, Harmer, SC, et al.. Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABCC8/KCNJ11 mutations. Diabetologia 2011;54:2575–83. https://doi.org/10.1007/s00125-011-2207-4.Suche in Google Scholar PubMed PubMed Central
22. Pinney, SE, MacMullen, C, Becker, S, Lin, YW, Hanna, C, Thornton, P, et al.. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest 2008;118:2877–86. https://doi.org/10.1172/jci35414.Suche in Google Scholar PubMed PubMed Central
23. Splawski, I, Timothy, KW, Vincent, GM, Atkinson, DL, Keating, MT. Molecular basis of the long-QT syndrome associated with deafness. N Engl J Med 1997;336:1562–7. https://doi.org/10.1056/nejm199705293362204.Suche in Google Scholar
24. Torekov, SS, Iepsen, E, Christiansen, M, Linneberg, A, Pedersen, O, Holst, JJ, et al.. KCNQ1 long QT syndrome patients have hyperinsulinemia and symptomatic hypoglycemia. Diabetes 2014;63:1315–25. https://doi.org/10.2337/db13-1454.Suche in Google Scholar PubMed
25. Iwashima, Y, Pugh, W, Depaoli, AM, Takeda, J, Seino, S, Bell, GI, et al.. Expression of calcium channel mRNAs in rat pancreatic islets and downregulation after glucose infusion. Diabetes 1993;42:948–55. https://doi.org/10.2337/diabetes.42.7.948.Suche in Google Scholar
26. Scholl, UI, Goh, G, Stolting, G, de Oliveira, RC, Choi, M, Overton, JD, et al.. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2013;45:1050–4. https://doi.org/10.1038/ng.2695.Suche in Google Scholar PubMed PubMed Central
27. Flanagan, SE, Vairo, F, Johnson, MB, Caswell, R, Laver, TW, Lango Allen, H, et al.. A CACNA1D mutation in a patient with persistent hyperinsulinaemic hypoglycaemia, heart defects, and severe hypotonia. Pediatr Diabetes 2017;18:320–3. https://doi.org/10.1111/pedi.12512.Suche in Google Scholar PubMed PubMed Central
28. Cuff, MA, Shirazi-Beechey, SP. The human monocarboxylate transporter, MCT1: genomic organization and promoter analysis. Biochem Biophys Res Commun 2002;292:1048–56. https://doi.org/10.1006/bbrc.2002.6763.Suche in Google Scholar PubMed
29. Pullen, TJ, Sylow, L, Sun, G, Halestrap, AP, Richter, EA, Rutter, GA. Overexpression of monocarboxylate transporter-1 (SLC16A1) in mouse pancreatic beta-cells leads to relative hyperinsulinism during exercise. Diabetes 2012;61:1719–25. https://doi.org/10.2337/db11-1531.Suche in Google Scholar PubMed PubMed Central
30. Meissner, T, Otonkoski, T, Feneberg, R, Beinbrech, B, Apostolidou, S, Sipila, I, et al.. Exercise induced hypoglycaemic hyperinsulinism. Arch Dis Child 2001;84:254–7. https://doi.org/10.1136/adc.84.3.254.Suche in Google Scholar PubMed PubMed Central
31. Otonkoski, T, Jiao, H, Kaminen-Ahola, N, Tapia-Paez, I, Ullah, MS, Parton, LE, et al.. Physical exercise-induced hypoglycemia caused by failed silencing of monocarboxylate transporter 1 in pancreatic beta cells. Am J Hum Genet 2007;81:467–74. https://doi.org/10.1086/520960.Suche in Google Scholar PubMed PubMed Central
32. Otonkoski, T, Kaminen, N, Ustinov, J, Lapatto, R, Meissner, T, Mayatepek, E, et al.. Physical exercise-induced hyperinsulinemic hypoglycemia is an autosomal-dominant trait characterized by abnormal pyruvate-induced insulin release. Diabetes 2003;52:199–204. https://doi.org/10.2337/diabetes.52.1.199.Suche in Google Scholar PubMed
33. Kelly, A, Ng, D, Ferry, RJJr., Grimberg, A, Koo-McCoy, S, Thornton, PS, et al.. Acute insulin responses to leucine in children with the hyperinsulinism/hyperammonemia syndrome. J Clin Endocrinol Metab 2001;86:3724–8. https://doi.org/10.1210/jcem.86.8.7755.Suche in Google Scholar PubMed PubMed Central
34. Li, C, Najafi, H, Daikhin, Y, Nissim, IB, Collins, HW, Yudkoff, M, et al.. Regulation of leucine-stimulated insulin secretion and glutamine metabolism in isolated rat islets. J Biol Chem 2003;278:2853–8. https://doi.org/10.1074/jbc.m210577200.Suche in Google Scholar PubMed
35. Kapoor, RR, Flanagan, SE, Fulton, P, Chakrapani, A, Chadefaux, B, Ben-Omran, T, et al.. Hyperinsulinism-hyperammonaemia syndrome: novel mutations in the GLUD1 gene and genotype-phenotype correlations. Eur J Endocrinol 2009;161:731–5. https://doi.org/10.1530/eje-09-0615.Suche in Google Scholar
36. Stanley, CA, Lieu, YK, Hsu, BY, Burlina, AB, Greenberg, CR, Hopwood, NJ, et al.. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med 1998;338:1352–7. https://doi.org/10.1056/nejm199805073381904.Suche in Google Scholar
37. Brandt, A, Agarwal, N, Giri, D, Yung, Z, Didi, M, Senniappan, S. Hyperinsulinism hyperammonaemia (HI/HA) syndrome due to GLUD1 mutation: phenotypic variations ranging from late presentation to spontaneous resolution. J Pediatr Endocrinol Metab 2020;33:675–9. https://doi.org/10.1515/jpem-2019-0416.Suche in Google Scholar PubMed
38. Glaser, B, Kesavan, P, Heyman, M, Davis, E, Cuesta, A, Buchs, A, et al.. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 1998;338:226–30. https://doi.org/10.1056/nejm199801223380404.Suche in Google Scholar
39. Martinez, R, Gutierrez-Nogues, A, Fernandez-Ramos, C, Velayos, T, Vela, A, Spanish Congenital Hyperinsulinism Group, et al.. Heterogeneity in phenotype of hyperinsulinism caused by activating glucokinase mutations: a novel mutation and its functional characterization. Clin Endocrinol 2017;86:778–83. https://doi.org/10.1111/cen.13318.Suche in Google Scholar PubMed
40. Cuesta-Munoz, AL, Huopio, H, Otonkoski, T, Gomez-Zumaquero, JM, Nanto-Salonen, K, Rahier, J, et al.. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 2004;53:2164–8. https://doi.org/10.2337/diabetes.53.8.2164.Suche in Google Scholar PubMed
41. Christesen, HB, Tribble, ND, Molven, A, Siddiqui, J, Sandal, T, Brusgaard, K, et al.. Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. Eur J Endocrinol 2008;159:27–34. https://doi.org/10.1530/eje-08-0203.Suche in Google Scholar
42. Pinney, SE, Ganapathy, K, Bradfield, J, Stokes, D, Sasson, A, Mackiewicz, K, et al.. Dominant form of congenital hyperinsulinism maps to HK1 region on 10q. Horm Res Paediatr 2013;80:18–27. https://doi.org/10.1159/000351943.Suche in Google Scholar PubMed PubMed Central
43. Henquin, JC, Sempoux, C, Marchandise, J, Godecharles, S, Guiot, Y, Nenquin, M, et al.. Congenital hyperinsulinism caused by hexokinase I expression or glucokinase-activating mutation in a subset of beta-cells. Diabetes 2013;62:1689–96. https://doi.org/10.2337/db12-1414.Suche in Google Scholar PubMed PubMed Central
44. Heslegrave, AJ, Kapoor, RR, Eaton, S, Chadefaux, B, Akcay, T, Simsek, E, et al.. Leucine-sensitive hyperinsulinaemic hypoglycaemia in patients with loss of function mutations in 3-hydroxyacyl-CoA dehydrogenase. Orphanet J Rare Dis 2012;7:25. https://doi.org/10.1186/1750-1172-7-25.Suche in Google Scholar PubMed PubMed Central
45. Filling, C, Keller, B, Hirschberg, D, Marschall, HU, Jornvall, H, Bennett, MJ, et al.. Role of short-chain hydroxyacyl CoA dehydrogenases in SCHAD deficiency. Biochem Biophys Res Commun 2008;368:6–11. https://doi.org/10.1016/j.bbrc.2007.10.188.Suche in Google Scholar PubMed
46. Babiker, O, Flanagan, SE, Ellard, S, Al Girim, H, Hussain, K, Senniappan, S. Protein-induced hyperinsulinaemic hypoglycaemia due to a homozygous HADH mutation in three siblings of a Saudi family. J Pediatr Endocrinol Metab 2015;28:1073–7. https://doi.org/10.1515/jpem-2015-0033.Suche in Google Scholar PubMed
47. Clayton, PT, Eaton, S, Aynsley-Green, A, Edginton, M, Hussain, K, Krywawych, S, et al.. Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion. J Clin Invest 2001;108:457–65. https://doi.org/10.1172/jci200111294.Suche in Google Scholar
48. Flanagan, SE, Patch, AM, Locke, JM, Akcay, T, Simsek, E, Alaei, M, et al.. Genome-wide homozygosity analysis reveals HADH mutations as a common cause of diazoxide-responsive hyperinsulinemic-hypoglycemia in consanguineous pedigrees. J Clin Endocrinol Metab 2011;96:E498–502. https://doi.org/10.1210/jc.2010-1906.Suche in Google Scholar PubMed PubMed Central
49. Fleury, C, Neverova, M, Collins, S, Raimbault, S, Champigny, O, Levi-Meyrueis, C, et al.. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 1997;15:269–72. https://doi.org/10.1038/ng0397-269.Suche in Google Scholar PubMed
50. Gonzalez-Barroso, MM, Giurgea, I, Bouillaud, F, Anedda, A, Bellanne-Chantelot, C, Hubert, L, et al.. Mutations in UCP2 in congenital hyperinsulinism reveal a role for regulation of insulin secretion. PLoS One 2008;3:e3850. https://doi.org/10.1371/journal.pone.0003850.Suche in Google Scholar PubMed PubMed Central
51. Ferrara, CT, Boodhansingh, KE, Paradies, E, Fiermonte, G, Steinkrauss, LJ, Topor, LS, et al.. Novel hypoglycemia phenotype in congenital hyperinsulinism due to dominant mutations of uncoupling protein 2. J Clin Endocrinol Metab 2017;102:942–9. https://doi.org/10.1210/jc.2016-3164.Suche in Google Scholar PubMed PubMed Central
52. Laver, TW, Weedon, MN, Caswell, R, Hussain, K, Ellard, S, Flanagan, SE. Analysis of large-scale sequencing cohorts does not support the role of variants in UCP2 as a cause of hyperinsulinaemic hypoglycaemia. Hum Mutat 2017;38:1442–4. https://doi.org/10.1002/humu.23289.Suche in Google Scholar PubMed PubMed Central
53. Tegtmeyer, LC, Rust, S, van Scherpenzeel, M, Ng, BG, Losfeld, ME, Timal, S, et al.. Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med 2014;370:533–42. https://doi.org/10.1056/nejmoa1206605.Suche in Google Scholar
54. Lee, HS, Qi, Y, Im, W. Effects of N-glycosylation on protein conformation and dynamics: Protein Data Bank analysis and molecular dynamics simulation study. Sci Rep 2015;5:8926. https://doi.org/10.1038/srep08926.Suche in Google Scholar PubMed PubMed Central
55. Cabezas, OR, Flanagan, SE, Stanescu, H, Garcia-Martinez, E, Caswell, R, Lango-Allen, H, et al.. Polycystic kidney disease with hyperinsulinemic hypoglycemia caused by a promoter mutation in phosphomannomutase 2. J Am Soc Nephrol 2017;28:2529–39. https://doi.org/10.1681/asn.2016121312.Suche in Google Scholar PubMed PubMed Central
56. Odom, DT, Zizlsperger, N, Gordon, DB, Bell, GW, Rinaldi, NJ, Murray, HL, et al.. Control of pancreas and liver gene expression by HNF transcription factors. Science 2004;303:1378–81. https://doi.org/10.1126/science.1089769.Suche in Google Scholar PubMed PubMed Central
57. Gupta, RK, Vatamaniuk, MZ, Lee, CS, Flaschen, RC, Fulmer, JT, Matschinsky, FM, et al.. The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion. J Clin Invest 2005;115:1006–15. https://doi.org/10.1172/jci200522365.Suche in Google Scholar
58. Arya, VB, Rahman, S, Senniappan, S, Flanagan, SE, Ellard, S, Hussain, K. HNF4A mutation: switch from hyperinsulinaemic hypoglycaemia to maturity-onset diabetes of the young, and incretin response. Diabet Med 2014;31:e11–5. https://doi.org/10.1111/dme.12369.Suche in Google Scholar PubMed PubMed Central
59. Dusatkova, P, Pruhova, S, Sumnik, Z, Kolouskova, S, Obermannova, B, Cinek, O, et al.. HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes. J Pediatr Endocrinol Metab 2011;24:377–9. https://doi.org/10.1515/jpem.2011.083.Suche in Google Scholar PubMed
60. Pearson, ER, Boj, SF, Steele, AM, Barrett, T, Stals, K, Shield, JP, et al.. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med 2007;4:e118. https://doi.org/10.1371/journal.pmed.0040118.Suche in Google Scholar PubMed PubMed Central
61. Rozenkova, K, Malikova, J, Nessa, A, Dusatkova, L, Bjorkhaug, L, Obermannova, B, et al.. High incidence of heterozygous ABCC8 and HNF1A mutations in Czech patients with congenital hyperinsulinism. J Clin Endocrinol Metab 2015;100:E1540–9. https://doi.org/10.1210/jc.2015-2763.Suche in Google Scholar PubMed
62. Hamilton, AJ, Bingham, C, McDonald, TJ, Cook, PR, Caswell, RC, Weedon, MN, et al.. The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a beta cell phenotype. J Med Genet 2014;51:165–9. https://doi.org/10.1136/jmedgenet-2013-102066.Suche in Google Scholar PubMed PubMed Central
63. Dayem-Quere, M, Giuliano, F, Wagner-Mahler, K, Massol, C, Crouzet-Ozenda, L, Lambert, JC, et al.. Delineation of a region responsible for panhypopituitarism in 20p11.2. Am J Med Genet A 2013;161A:1547–54. https://doi.org/10.1002/ajmg.a.35921.Suche in Google Scholar PubMed
64. Gao, N, LeLay, J, Vatamaniuk, MZ, Rieck, S, Friedman, JR, Kaestner, KH. Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. Genes Dev 2008;22:3435–48. https://doi.org/10.1101/gad.1752608.Suche in Google Scholar PubMed PubMed Central
65. Sund, NJ, Vatamaniuk, MZ, Casey, M, Ang, SL, Magnuson, MA, Stoffers, DA, et al.. Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia. Genes Dev 2001;15:1706–15. https://doi.org/10.1101/gad.901601.Suche in Google Scholar PubMed PubMed Central
66. Giri, D, Vignola, ML, Gualtieri, A, Scagliotti, V, McNamara, P, Peak, M, et al.. Novel FOXA2 mutation causes hyperinsulinism, hypopituitarism with craniofacial and endoderm-derived organ abnormalities. Hum Mol Genet 2017;26:4315–26. https://doi.org/10.1093/hmg/ddx318.Suche in Google Scholar PubMed
67. Vajravelu, ME, Chai, J, Krock, B, Baker, S, Langdon, D, Alter, C, et al.. Congenital hyperinsulinism and hypopituitarism attributable to a mutation in FOXA2. J Clin Endocrinol Metab 2018;103:1042–7. https://doi.org/10.1210/jc.2017-02157.Suche in Google Scholar PubMed PubMed Central
68. Dines, JN, Liu, YJ, Neufeld-Kaiser, W, Sawyer, T, Ishak, GE, Tully, HM, et al.. Expanding phenotype with severe midline brain anomalies and missense variant supports a causal role for FOXA2 in 20p11.2 deletion syndrome. Am J Med Genet A 2019;179:1783–90. https://doi.org/10.1002/ajmg.a.61281.Suche in Google Scholar PubMed
69. Mohammed, I, Al-Khawaga, S, Bohanna, D, Shabani, A, Khan, F, Love, DR, et al.. Haploinsufficiency of the FOXA2 associated with a complex clinical phenotype. Mol Genet Genomic Med 2020;8:e1086. https://doi.org/10.1002/mgg3.1086.Suche in Google Scholar PubMed PubMed Central
70. Stekelenburg, C, Gerster, K, Blouin, JL, Lang-Muritano, M, Guipponi, M, Santoni, F, et al.. Exome sequencing identifies a de novo FOXA2 variant in a patient with syndromic diabetes. Pediatr Diabetes 2019;20:366–9. https://doi.org/10.1111/pedi.12814.Suche in Google Scholar PubMed
71. Gregory, LC, Ferreira, CB, Young-Baird, SK, Williams, HJ, Harakalova, M, van Haaften, G, et al.. Impaired EIF2S3 function associated with a novel phenotype of X-linked hypopituitarism with glucose dysregulation. EBioMedicine 2019;42:470–80. https://doi.org/10.1016/j.ebiom.2019.03.013.Suche in Google Scholar
72. Yap, F, Hogler, W, Vora, A, Halliday, R, Ambler, G. Severe transient hyperinsulinaemic hypoglycaemia: two neonates without predisposing factors and a review of the literature. Eur J Pediatr 2004;163:38–41. https://doi.org/10.1007/s00431-003-1328-2.Suche in Google Scholar
73. Fafoula, O, Alkhayyat, H, Hussain, K. Prolonged hyperinsulinaemic hypoglycaemia in newborns with intrauterine growth retardation. Arch Dis Child Fetal Neonatal Ed 2006;91:F467. https://doi.org/10.1136/adc.2006.095919.Suche in Google Scholar
74. Shah, P, Rahman, SA, Demirbilek, H, Guemes, M, Hussain, K. Hyperinsulinaemic hypoglycaemia in children and adults. Lancet Diabetes Endocrinol 2017;5:729–42. https://doi.org/10.1016/s2213-8587(16)30323-0.Suche in Google Scholar
75. Ferrara, C, Patel, P, Becker, S, Stanley, CA, Kelly, A. Biomarkers of insulin for the diagnosis of hyperinsulinemic hypoglycemia in infants and children. J Pediatr 2016;168:212–9. https://doi.org/10.1016/j.jpeds.2015.09.045.Suche in Google Scholar
76. Gupsilonemes, M, Rahman, SA, Kapoor, RR, Flanagan, S, Houghton, JAL, Misra, S, et al.. Hyperinsulinemic hypoglycemia in children and adolescents: recent advances in understanding of pathophysiology and management. Rev Endocr Metab Disord 2020;21:577–97.10.1007/s11154-020-09548-7Suche in Google Scholar
77. Brady, C, Palladino, AA, Gutmark-Little, I. A novel case of compound heterozygous congenital hyperinsulinism without high insulin levels. Int J Pediatr Endocrinol 2015;2015:16. https://doi.org/10.1186/s13633-015-0012-4.Suche in Google Scholar
78. Palladino, AA, Bennett, MJ, Stanley, CA. Hyperinsulinism in infancy and childhood: when an insulin level is not always enough. Clin Chem 2008;54:256–63. https://doi.org/10.1373/clinchem.2007.098988.Suche in Google Scholar
79. Levitt Katz, LE, Satin-Smith, MS, Collett-Solberg, P, Thornton, PS, Baker, L, Stanley, CA, et al.. Insulin-like growth factor binding protein-1 levels in the diagnosis of hypoglycemia caused by hyperinsulinism. J Pediatr 1997;131:193–9. https://doi.org/10.1016/s0022-3476(97)70153-7.Suche in Google Scholar
80. Hsu, BY, Kelly, A, Thornton, PS, Greenberg, CR, Dilling, LA, Stanley, CA. Protein-sensitive and fasting hypoglycemia in children with the hyperinsulinism/hyperammonemia syndrome. J Pediatr 2001;138:383–9. https://doi.org/10.1067/mpd.2001.111818.Suche in Google Scholar PubMed
81. Arnoux, JB, Verkarre, V, Saint-Martin, C, Montravers, F, Brassier, A, Valayannopoulos, V, et al.. Congenital hyperinsulinism: current trends in diagnosis and therapy. Orphanet J Rare Dis 2011;6:63. https://doi.org/10.1186/1750-1172-6-63.Suche in Google Scholar PubMed PubMed Central
82. Neylon, OM, Moran, MM, Pellicano, A, Nightingale, M, O’Connell, MA. Successful subcutaneous glucagon use for persistent hypoglycaemia in congenital hyperinsulinism. J Pediatr Endocrinol Metab 2013;26:1157–61. https://doi.org/10.1515/jpem-2013-0115.Suche in Google Scholar PubMed
83. Maiorana, A, Barbetti, F, Boiani, A, Rufini, V, Pizzoferro, M, Francalanci, P, et al.. Focal congenital hyperinsulinism managed by medical treatment: a diagnostic algorithm based on molecular genetic screening. Clin Endocrinol 2014;81:679–88. https://doi.org/10.1111/cen.12400.Suche in Google Scholar PubMed
84. Timlin, MR, Black, AB, Delaney, HM, Matos, RI, Percival, CS. Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. Pediatr Cardiol 2017;38:1247–50. https://doi.org/10.1007/s00246-017-1652-3.Suche in Google Scholar PubMed
85. Chen, SC, Dastamani, A, Pintus, D, Yau, D, Aftab, S, Bath, L, et al.. Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: recommendations from a multicentre study in the United Kingdom. Clin Endocrinol 2019;91:770–5. https://doi.org/10.1111/cen.14096.Suche in Google Scholar PubMed
86. Giri, D, Price, V, Yung, Z, Didi, M, Senniappan, S. Fluoxetine-induced hypoglycaemia in a patient with congenital hyperinsulinism on lanreotide therapy. J Clin Res Pediatr Endocrinol 2016;8:347–50. https://doi.org/10.4274/jcrpe.2818.Suche in Google Scholar PubMed PubMed Central
87. Lord, K, De Leon, DD. Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management. Int J Pediatr Endocrinol 2013;2013:3. https://doi.org/10.1186/1687-9856-2013-3.Suche in Google Scholar PubMed PubMed Central
88. Katz, MD, Erstad, BL. Octreotide, a new somatostatin analogue. Clin Pharm 1989;8:255–73.Suche in Google Scholar
89. Hussain, K. Diagnosis and management of hyperinsulinaemic hypoglycaemia of infancy. Horm Res 2008;69:2–13. https://doi.org/10.1159/000111789.Suche in Google Scholar PubMed
90. Yorifuji, T, Kawakita, R, Hosokawa, Y, Fujimaru, R, Matsubara, K, Aizu, K, et al.. Efficacy and safety of long-term, continuous subcutaneous octreotide infusion for patients with different subtypes of KATP-channel hyperinsulinism. Clin Endocrinol 2013;78:891–7. https://doi.org/10.1111/cen.12075.Suche in Google Scholar PubMed
91. Escorsell, A, Bandi, JC, Andreu, V, Moitinho, E, Garcia-Pagan, JC, Bosch, J, et al.. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001;120:161–9. https://doi.org/10.1053/gast.2001.20892.Suche in Google Scholar PubMed
92. Wahid, ST, Marbach, P, Stolz, B, Miller, M, James, RA, Ball, SG. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol 2002;146:295–302. https://doi.org/10.1530/eje.0.1460295.Suche in Google Scholar
93. Hosokawa, Y, Kawakita, R, Yokoya, S, Ogata, T, Ozono, K, Arisaka, O, et al.. Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry. Endocr J 2017;64:867–80. https://doi.org/10.1507/endocrj.ej17-0024.Suche in Google Scholar
94. Thornton, PS, Alter, CA, Katz, LE, Baker, L, Stanley, CA. Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 1993;123:637–43. https://doi.org/10.1016/s0022-3476(05)80969-2.Suche in Google Scholar
95. Petersen, H, Bizec, JC, Schuetz, H, Delporte, ML. Pharmacokinetic and technical comparison of Sandostatin(R) LAR(R) and other formulations of long-acting octreotide. BMC Res Notes 2011;4:344. https://doi.org/10.1186/1756-0500-4-344.Suche in Google Scholar PubMed PubMed Central
96. Shah, P, Rahman, SA, McElroy, S, Gilbert, C, Morgan, K, Hinchey, L, et al.. Use of long-acting somatostatin analogue (lanreotide) in an adolescent with diazoxide-responsive congenital hyperinsulinism and its psychological impact. Horm Res Paediatr 2015;84:355–60. https://doi.org/10.1159/000439131.Suche in Google Scholar PubMed
97. Corda, H, Kummer, S, Welters, A, Teig, N, Klee, D, Mayatepek, E, et al.. Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism. Orphanet J Rare Dis 2017;12:108. https://doi.org/10.1186/s13023-017-0653-x.Suche in Google Scholar PubMed PubMed Central
98. van der Steen, I, van Albada, ME, Mohnike, K, Christesen, HT, Empting, S, Salomon-Estebanez, M, et al.. A multicenter experience with long-acting somatostatin analogues in patients with congenital hyperinsulinism. Horm Res Paediatr 2018;89:82–9. https://doi.org/10.1159/000485184.Suche in Google Scholar PubMed
99. Dastamani, A, Guemes, M, Pitfield, C, Morgan, K, Rajab, M, Rottenburger, C, et al.. The use of a long-acting somatostatin analogue (lanreotide) in three children with focal forms of congenital hyperinsulinaemic hypoglycaemia. Horm Res Paediatr 2019;91:56–61. https://doi.org/10.1159/000491101.Suche in Google Scholar PubMed
100. Mergler, S, Singh, V, Grotzinger, C, Kaczmarek, P, Wiedenmann, B, Strowski, MZ. Characterization of voltage operated R-type Ca2+ channels in modulating somatostatin receptor subtype 2- and 3-dependent inhibition of insulin secretion from INS-1 cells. Cell Signal 2008;20:2286–95. https://doi.org/10.1016/j.cellsig.2008.08.015.Suche in Google Scholar PubMed
101. Durmaz, E, Flanagan, SE, Parlak, M, Ellard, S, Akcurin, S, Bircan, I. A combination of nifedipine and octreotide treatment in an hyperinsulinemic hypoglycemic infant. J Clin Res Pediatr Endocrinol 2014;6:119–21. https://doi.org/10.4274/jcrpe.1230.Suche in Google Scholar
102. Welters, A, Lerch, C, Kummer, S, Marquard, J, Salgin, B, Mayatepek, E, et al.. Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers. Orphanet J Rare Dis 2015;10:150. https://doi.org/10.1186/s13023-015-0367-x.Suche in Google Scholar PubMed PubMed Central
103. Guemes, M, Shah, P, Silvera, S, Morgan, K, Gilbert, C, Hinchey, L, et al.. Assessment of nifedipine therapy in hyperinsulinemic hypoglycemia due to mutations in the ABCC8 gene. J Clin Endocrinol Metab 2017;102:822–30. https://doi.org/10.1210/jc.2016-2916.Suche in Google Scholar PubMed
104. Mohnike, K, Blankenstein, O, Pfuetzner, A, Potzsch, S, Schober, E, Steiner, S, et al.. Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res 2008;70:59–64. https://doi.org/10.1159/000129680.Suche in Google Scholar PubMed
105. Brun, JF, Fedou, C, Mercier, J. Postprandial reactive hypoglycemia. Diabetes Metab 2000;26:337–51.Suche in Google Scholar
106. Salvatore, T, Giugliano, D. Pharmacokinetic-pharmacodynamic relationships of acarbose. Clin Pharmacokinet 1996;30:94–106. https://doi.org/10.2165/00003088-199630020-00002.Suche in Google Scholar PubMed
107. Skae, M, Avatapalle, HB, Banerjee, I, Rigby, L, Vail, A, Foster, P, et al.. Reduced glycemic variability in diazoxide-responsive children with congenital hyperinsulinism using supplemental omega-3-polyunsaturated fatty acids; a pilot trial with MaxEPA(R.). Front Endocrinol 2014;5:31. https://doi.org/10.3389/fendo.2014.00031.Suche in Google Scholar PubMed PubMed Central
108. Yang, SB, Lee, HY, Young, DM, Tien, AC, Rowson-Baldwin, A, Shu, YY, et al.. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J Mol Med 2012;90:575–85. https://doi.org/10.1007/s00109-011-0834-3.Suche in Google Scholar PubMed PubMed Central
109. Kulke, MH, Bergsland, EK, Yao, JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009;360:195–7. https://doi.org/10.1056/nejmc0806740.Suche in Google Scholar
110. Alexandrescu, S, Tatevian, N, Olutoye, O, Brown, RE. Persistent hyperinsulinemic hypoglycemia of infancy: constitutive activation of the mTOR pathway with associated exocrine-islet transdifferentiation and therapeutic implications. Int J Clin Exp Pathol 2010;3:691–705.Suche in Google Scholar
111. Senniappan, S, Alexandrescu, S, Tatevian, N, Shah, P, Arya, V, Flanagan, S, et al.. Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. N Engl J Med 2014;370:1131–7. https://doi.org/10.1056/nejmoa1310967.Suche in Google Scholar
112. Banerjee, I, De Leon, D, Dunne, MJ. Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient. Orphanet J Rare Dis 2017;12:70. https://doi.org/10.1186/s13023-017-0621-5.Suche in Google Scholar PubMed PubMed Central
113. Maria, G, Antonia, D, Michael, A, Kate, M, Sian, E, Sarah, FE, et al.. Sirolimus: efficacy and complications in children with hyperinsulinemic hypoglycemia: a 5-year follow-up study. J Endocr Soc 2019;3:699–713. https://doi.org/10.1210/js.2018-00417.Suche in Google Scholar PubMed PubMed Central
114. Sankhala, K, Mita, A, Kelly, K, Mahalingam, D, Giles, F, Mita, M. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Targeted Oncol 2009;4:135–42. https://doi.org/10.1007/s11523-009-0107-z.Suche in Google Scholar PubMed
115. De Leon, DD, Crutchlow, MF, Ham, JY, Stoffers, DA. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 2006;38:845–59. https://doi.org/10.1016/j.biocel.2005.07.011.Suche in Google Scholar PubMed
116. Renstrom, E, Eliasson, L, Rorsman, P. Protein kinase A-dependent and -independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells. J Physiol 1997;502:105–18. https://doi.org/10.1111/j.1469-7793.1997.105bl.x.Suche in Google Scholar PubMed PubMed Central
117. De Leon, DD, Li, C, Delson, MI, Matschinsky, FM, Stanley, CA, Stoffers, DA. Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion. J Biol Chem 2008;283:25786–93. https://doi.org/10.1074/jbc.m804372200.Suche in Google Scholar
118. Calabria, AC, Li, C, Gallagher, PR, Stanley, CA, De Leon, DD. GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel. Diabetes 2012;61:2585–91. https://doi.org/10.2337/db12-0166.Suche in Google Scholar PubMed PubMed Central
119. Chen, PC, Olson, EM, Zhou, Q, Kryukova, Y, Sampson, HM, Thomas, DY, et al.. Carbamazepine as a novel small molecule corrector of trafficking-impaired ATP-sensitive potassium channels identified in congenital hyperinsulinism. J Biol Chem 2013;288:20942–54. https://doi.org/10.1074/jbc.m113.470948.Suche in Google Scholar
120. Yan, F, Lin, CW, Weisiger, E, Cartier, EA, Taschenberger, G, Shyng, SL. Sulfonylureas correct trafficking defects of ATP-sensitive potassium channels caused by mutations in the sulfonylurea receptor. J Biol Chem 2004;279:11096–105. https://doi.org/10.1074/jbc.m312810200.Suche in Google Scholar
121. Silverstein, JM. Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly. Pituitary 2016;19:536–43. https://doi.org/10.1007/s11102-016-0734-1.Suche in Google Scholar PubMed PubMed Central
122. Mooij, CF, Tacke, CE, van Albada, ME, Barthlen, W, Bikker, H, Mohnike, K, et al.. First report on the use of pasireotide in a case of severe congenital hyperinsulinism due to a homozygous ABCC8 mutation. Ann Pediatr Endocrinol Metab 2021. https://doi.org/10.6065/apem.2142010.005.Suche in Google Scholar PubMed PubMed Central
123. Patel, P, Charles, L, Corbin, J, Goldfine, ID, Johnson, K, Rubin, P, et al.. A unique allosteric insulin receptor monoclonal antibody that prevents hypoglycemia in the SUR-1(-/-) mouse model of KATP hyperinsulinism. MAbs 2018;10:796–802. https://doi.org/10.1080/19420862.2018.1457599.Suche in Google Scholar PubMed PubMed Central
124. Maiorana, A, Manganozzi, L, Barbetti, F, Bernabei, S, Gallo, G, Cusmai, R, et al.. Ketogenic diet in a patient with congenital hyperinsulinism: a novel approach to prevent brain damage. Orphanet J Rare Dis 2015;10:120. https://doi.org/10.1186/s13023-015-0342-6.Suche in Google Scholar
125. Sempoux, C, Guiot, Y, Jaubert, F, Rahier, J. Focal and diffuse forms of congenital hyperinsulinism: the keys for differential diagnosis. Endocr Pathol 2004;15:241–6. https://doi.org/10.1385/ep:15:3:241.10.1385/EP:15:3:241Suche in Google Scholar
126. Rahier, J, Guiot, Y, Sempoux, C. Morphologic analysis of focal and diffuse forms of congenital hyperinsulinism. Semin Pediatr Surg 2011;20:3–12. https://doi.org/10.1053/j.sempedsurg.2010.10.010.Suche in Google Scholar PubMed
127. Verkarre, V, Fournet, JC, de Lonlay, P, Gross-Morand, MS, Devillers, M, Rahier, J, et al.. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. J Clin Invest 1998;102:1286–91. https://doi.org/10.1172/jci4495.Suche in Google Scholar PubMed PubMed Central
128. Damaj, L, le Lorch, M, Verkarre, V, Werl, C, Hubert, L, Nihoul-Fekete, C, et al.. Chromosome 11p15 paternal isodisomy in focal forms of neonatal hyperinsulinism. J Clin Endocrinol Metab 2008;93:4941–7. https://doi.org/10.1210/jc.2008-0673.Suche in Google Scholar PubMed
129. Lord, K, Dzata, E, Snider, KE, Gallagher, PR, De Leon, DD. Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases. J Clin Endocrinol Metab 2013;98:E1786–9. https://doi.org/10.1210/jc.2013-2094.Suche in Google Scholar PubMed PubMed Central
130. Han, B, Newbould, M, Batra, G, Cheesman, E, Craigie, RJ, Mohamed, Z, et al.. Enhanced islet cell nucleomegaly defines diffuse congenital hyperinsulinism in infancy but not other forms of the disease. Am J Clin Pathol 2016;145:757–68. https://doi.org/10.1093/ajcp/aqw075.Suche in Google Scholar PubMed PubMed Central
131. Zhang, W, Liu, L, Wen, Z, Cheng, J, Li, C, Li, X, et al.. A compound heterozygous mutation of ABCC8 gene causing a diazoxide-unresponsive congenital hyperinsulinism with an atypical form: not a focal lesion in the pancreas reported by (1)(8)F-DOPA-PET/CT scan. Gene 2015;572:222–6. https://doi.org/10.1016/j.gene.2015.07.012.Suche in Google Scholar PubMed
132. Capito, C, de Lonlay, P, Verkarre, V, Jaubert, F, Rahier, J, Nihoul-Fekete, C, et al.. The surgical management of atypical forms of congenital hyperinsulinism. Semin Pediatr Surg 2011;20:54–5. https://doi.org/10.1053/j.sempedsurg.2010.10.003.Suche in Google Scholar PubMed
133. Sempoux, C, Capito, C, Bellanne-Chantelot, C, Verkarre, V, de Lonlay, P, Aigrain, Y, et al.. Morphological mosaicism of the pancreatic islets: a novel anatomopathological form of persistent hyperinsulinemic hypoglycemia of infancy. J Clin Endocrinol Metab 2011;96:3785–93. https://doi.org/10.1210/jc.2010-3032.Suche in Google Scholar PubMed
134. Hussain, K, Flanagan, SE, Smith, VV, Ashworth, M, Day, M, Pierro, A, et al.. An ABCC8 gene mutation and mosaic uniparental isodisomy resulting in atypical diffuse congenital hyperinsulinism. Diabetes 2008;57:259–63. https://doi.org/10.2337/db07-0998.Suche in Google Scholar PubMed
135. Blomberg, BA, Moghbel, MC, Saboury, B, Stanley, CA, Alavi, A. The value of radiologic interventions and (18)F-DOPA PET in diagnosing and localizing focal congenital hyperinsulinism: systematic review and meta-analysis. Mol Imag Biol 2013;15:97–105. https://doi.org/10.1007/s11307-012-0572-0.Suche in Google Scholar PubMed PubMed Central
136. Capito, C, Khen-Dunlop, N, Ribeiro, MJ, Brunelle, F, Aigrain, Y, Cretolle, C, et al.. Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism. Radiology 2009;253:216–22. https://doi.org/10.1148/radiol.2532081445.Suche in Google Scholar PubMed
137. Otonkoski, T, Nanto-Salonen, K, Seppanen, M, Veijola, R, Huopio, H, Hussain, K, et al.. Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes 2006;55:13–8. https://doi.org/10.2337/diabetes.55.01.06.db05-1128.Suche in Google Scholar
138. Christiansen, CD, Petersen, H, Nielsen, AL, Detlefsen, S, Brusgaard, K, Rasmussen, L, et al.. 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation. Eur J Nucl Med Mol Imag 2018;45:250–61. https://doi.org/10.1007/s00259-017-3867-1.Suche in Google Scholar PubMed PubMed Central
139. Al-Shanafey, S. Laparoscopic vs open pancreatectomy for persistent hyperinsulinemic hypoglycemia of infancy. J Pediatr Surg 2009;44:957–61. https://doi.org/10.1016/j.jpedsurg.2009.01.042.Suche in Google Scholar PubMed
140. Laje, P, Stanley, CA, Palladino, AA, Becker, SA, Adzick, NS. Pancreatic head resection and Roux-en-Y pancreaticojejunostomy for the treatment of the focal form of congenital hyperinsulinism. J Pediatr Surg 2012;47:130–5. https://doi.org/10.1016/j.jpedsurg.2011.10.032.Suche in Google Scholar PubMed PubMed Central
141. Rahier, J, Sempoux, C, Fournet, JC, Poggi, F, Brunelle, F, Nihoul-Fekete, C, et al.. Partial or near-total pancreatectomy for persistent neonatal hyperinsulinaemic hypoglycaemia: the pathologist’s role. Histopathology 1998;32:15–9. https://doi.org/10.1046/j.1365-2559.1998.00326.x.Suche in Google Scholar PubMed
142. Beltrand, J, Caquard, M, Arnoux, JB, Laborde, K, Velho, G, Verkarre, V, et al.. Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. Diabetes Care 2012;35:198–203. https://doi.org/10.2337/dc11-1296.Suche in Google Scholar PubMed PubMed Central
143. Shah, P, Demirbilek, H, Hussain, K. Persistent hyperinsulinaemic hypoglycaemia in infancy. Semin Pediatr Surg 2014;23:76–82. https://doi.org/10.1053/j.sempedsurg.2014.03.005.Suche in Google Scholar PubMed
144. Arya, VB, Senniappan, S, Demirbilek, H, Alam, S, Flanagan, SE, Ellard, S, et al.. Pancreatic endocrine and exocrine function in children following near-total pancreatectomy for diffuse congenital hyperinsulinism. PLoS One 2014;9:e98054. https://doi.org/10.1371/journal.pone.0098054.Suche in Google Scholar PubMed PubMed Central
145. Salomon-Estebanez, M, Flanagan, SE, Ellard, S, Rigby, L, Bowden, L, Mohamed, Z, et al.. Conservatively treated Congenital Hyperinsulinism (CHI) due to K-ATP channel gene mutations: reducing severity over time. Orphanet J Rare Dis 2016;11:163. https://doi.org/10.1186/s13023-016-0547-3.Suche in Google Scholar PubMed PubMed Central
146. Alsaffar, H, Turner, L, Yung, Z, Didi, M, Senniappan, S. Continuous flash glucose monitoring in children with congenital hyperinsulinism; first report on accuracy and patient experience. Int J Pediatr Endocrinol 2018;2018:3. https://doi.org/10.1186/s13633-018-0057-2.Suche in Google Scholar PubMed PubMed Central
147. Menni, F, de Lonlay, P, Sevin, C, Touati, G, Peigne, C, Barbier, V, et al.. Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia. Pediatrics 2001;107:476–9. https://doi.org/10.1542/peds.107.3.476.Suche in Google Scholar PubMed
148. Ludwig, A, Enke, S, Heindorf, J, Empting, S, Meissner, T, Mohnike, K. Formal neurocognitive testing in 60 patients with congenital hyperinsulinism. Horm Res Paediatr 2018;89:1–6. https://doi.org/10.1159/000481774.Suche in Google Scholar PubMed
149. Muukkonen, L, Mannisto, J, Jaaskelainen, J, Hannonen, R, Huopio, H. The effect of hypoglycaemia on neurocognitive outcome in children and adolescents with transient or persistent congenital hyperinsulinism. Dev Med Child Neurol 2019;61:451–7. https://doi.org/10.1111/dmcn.14039.Suche in Google Scholar PubMed
© 2021 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- Frontmatter
- Review Article
- Congenital hyperinsulinism: recent updates on molecular mechanisms, diagnosis and management
- Original Articles
- Weight changes of children in 1 year during COVID-19 pandemic
- Three novel mutations of the BCKDHA, BCKDHB and DBT genes in Chinese children with maple syrup urine disease
- Rates of adrenal insufficiency using a monoclonal vs. polyclonal cortisol assay
- Hyperinsulinemic hypoglycemia in growth restricted convalescent preterm neonates: clinical characteristics and impediments to early diagnosis
- Identification of three novel pathogenic mutations in cystathionine beta-synthase gene of Pakistani intellectually disabled patients
- The prevalence of incidental finding of gynecomastia on thoracic computed tomography in the pediatric age group
- The prevalence of hypertension and elevated blood pressure and its correlation with overweight/obesity among students aged 6–17 years in Suzhou
- Investigation of androgen receptor gene CAG repeat length polymorphism in pubertal gynecomastia
- A single-centre study of genetic mutations, audiology, echocardiogram and pulmonary function in Saudi children with osteogenesis imperfecta
- A 10-year retrospective single-center study of alpha-fetoprotein and beta-human chorionic gonadotropin in Romanian children with (para)gonadal tumors and cysts
- Clinical, pathological and molecular spectrum of patients with glycogen storage diseases in Pakistan
- Allelic dropout in PAH affecting the results of genetic diagnosis in phenylketonuria
- Short Communication
- Role of the SARS-CoV-2 virus in the appearance of new onset type 1 diabetes mellitus in children in Gran Canaria, Spain
- Case Reports
- 3-M syndrome – a primordial short stature disorder with novel CUL7 mutation in two Indian patients
- The coincidence of two rare diseases with opposite metabolic phenotype: a child with congenital hyperinsulinism and Bloom syndrome
- Growth hormone deficiency in a child with benign hereditary chorea caused by a de novo mutation of the TITF1/NKX2-1 gene
- Identification of a novel mutation in the PHKA2 gene in a child with liver cirrhosis
Artikel in diesem Heft
- Frontmatter
- Review Article
- Congenital hyperinsulinism: recent updates on molecular mechanisms, diagnosis and management
- Original Articles
- Weight changes of children in 1 year during COVID-19 pandemic
- Three novel mutations of the BCKDHA, BCKDHB and DBT genes in Chinese children with maple syrup urine disease
- Rates of adrenal insufficiency using a monoclonal vs. polyclonal cortisol assay
- Hyperinsulinemic hypoglycemia in growth restricted convalescent preterm neonates: clinical characteristics and impediments to early diagnosis
- Identification of three novel pathogenic mutations in cystathionine beta-synthase gene of Pakistani intellectually disabled patients
- The prevalence of incidental finding of gynecomastia on thoracic computed tomography in the pediatric age group
- The prevalence of hypertension and elevated blood pressure and its correlation with overweight/obesity among students aged 6–17 years in Suzhou
- Investigation of androgen receptor gene CAG repeat length polymorphism in pubertal gynecomastia
- A single-centre study of genetic mutations, audiology, echocardiogram and pulmonary function in Saudi children with osteogenesis imperfecta
- A 10-year retrospective single-center study of alpha-fetoprotein and beta-human chorionic gonadotropin in Romanian children with (para)gonadal tumors and cysts
- Clinical, pathological and molecular spectrum of patients with glycogen storage diseases in Pakistan
- Allelic dropout in PAH affecting the results of genetic diagnosis in phenylketonuria
- Short Communication
- Role of the SARS-CoV-2 virus in the appearance of new onset type 1 diabetes mellitus in children in Gran Canaria, Spain
- Case Reports
- 3-M syndrome – a primordial short stature disorder with novel CUL7 mutation in two Indian patients
- The coincidence of two rare diseases with opposite metabolic phenotype: a child with congenital hyperinsulinism and Bloom syndrome
- Growth hormone deficiency in a child with benign hereditary chorea caused by a de novo mutation of the TITF1/NKX2-1 gene
- Identification of a novel mutation in the PHKA2 gene in a child with liver cirrhosis